Search Results - "Kruit, W.H.J."

The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence by Leeneman, B, Franken, M.G, Blommestein, H.M, van Gils, C.W.M, van der Meijde, E, Wouters, M.W.J.M, Plaisier, P.W, Kruit, W.H.J, van Ruth, S, ten Tije, A.J, Hendriks, M.P, Coupe, V.M.H, Uyl- de Groot, CA

Get full text

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma by Van Gool, A R, Verkerk, R, Fekkes, D, Sleijfer, S, Bannink, M, Kruit, W H J, van der Holt, B, Scharpé, S, Eggermont, A M M, Stoter, G, Hengeveld, M W

“…Abnormal activity in peripheral blood of the cytosolic enzyme prolyl endopeptidase (PEP, EC 3.4.21.26, post prolyl cleaving enzyme, prolyl oligopeptidase) has…”
Get more information

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients by Van Gool, A R, Van Ojik, H H, Kruit, W H J, Mulder, P G H, Fekkes, D, Bannink, M, Scharpé, S, Stoter, G, Eggermont, A M M, Maes, M, Verkerk, R

“…Immunotherapy with interferon-alpha (IFN-alpha) induces neuropsychiatric side effects, most notably depression. In hepatitis patients treated with IFN-alpha,…”
Get more information

Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma by Boekhout, A.H., Hauptmann, M., van den Eertwegh, A.J.M., Hospers, G.A.P., de Groot, J.W.B., Aarts, M.J.B., Kapiteijn, E., Ten Tije, A.J., Piersma, D., Kruit, W.H.J., Suijkerbuijk, K.P.M., Berkmortel, F.W.P.J., Vreugdenhil, G., Koornstra, R.H., Fiets, E., Lees, M., Janssen, K.J.M., van den Poll-Franse, L.V., Blank, C.U.

Get full text

Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma by Boekhout, A.H., Hauptmann, M., van den Eertwegh, A.J.M., Hospers, G.A.P., de Groot, J.W.B., Aarts, M.J.B., Kapiteijn, E., Ten Tije, A.J., Piersma, D., Kruit, W.H.J., Suijkerbuijk, K.P.M., Berkmortel, F.W.P.J., Vreugdenhil, G., Koornstra, R.H., Fiets, E., Lees, M., Janssen, K.J.M., van den Poll-Franse, L.V., Blank, C.U.

Get full text

PCN29 - The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence by Leeneman, B., Franken, M.G., Blommestein, H.M., van Gils, C.W.M., van der Meijde, E., Wouters, M.W.J.M., Plaisier, P.W., Kruit, W.H.J., van Ruth, S., ten Tije, A.J., Hendriks, M.P., Coupe, V.M.H., Uyl- de Groot, CA

Get full text

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report by Marchand, M, Punt, C.J.A, Aamdal, S, Escudier, B, Kruit, W.H.J, Keilholz, U, Håkansson, L, van Baren, N, Humblet, Y, Mulders, P, Avril, M.-F, Eggermont, A.M.M, Scheibenbogen, C, Uiters, J, Wanders, J, Delire, M, Boon, T, Stoter, G

“…Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant…”
Get full text

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma by Kivelä, T, Suciu, S, Hansson, J, Kruit, W.H.J, Vuoristo, M.-S, Kloke, O, Gore, M, Hahka-Kemppinen, M, Parvinen, L.-M, Kumpulainen, E, Humblet, Y, Pyrhönen, S

“…This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with…”
Get full text

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group by Punt, C.J.A., Suciu, S., Gore, M.A., Koller, J., Kruit, W.H.J., Thomas, J., Patel, P., Lienard, D., Eggermont, A.M.M., Keilholz, U.

“…Chemoimmunotherapy for patients with metastatic melanoma is associated with high toxicity, and only a subset of patients will benefit. This randomised phase II…”
Get full text

P.2.h.001 Nitric oxide production and psychiatric symptomatology after interferon-a therapy in oncology patients by Fekkes, D, Bannink, M, Sleijfer, S, Van Gool, A.R, Kruit, W.H.J, van de Holt, B, Eggermont, A.M.M, Hengeveld, M.W, Stoter, G

Get full text

P.1.076 Influence of immunotherapy with pegylatedinterferon-alpha on platelet monoamine oxidase activity in high-risk melanoma patients by Fekkes, D., van Goof, A.R., van Ojik, H.H., Bannink, M., Mulder, R.G.H., Kruit, W.H.J., Eggermont, A.M.M., Stoter, G.

Get full text

Influence of immunotherapy with interferon-alpha on serum amino acids, biopterin and neopterin in high risk melanoma patients by Van Gool, A.R., Fekkers, D., Kruit, W.H.J., Ten Hagen, T.L.M., Bannink, M., Maes, M., Eggermont, A.M.M.

Get full text

Interferon-α induced Raynaud's syndrome by Kruit, W. H. J., Eggermont, A. M. M., Stoter, G.

“…The cytokine interferon-alpha (IFN-α) is increasingly prescribed for a number of indications, especially viral hepatitis and several malignancies. Two patients…”
Get full text

Weekly high dose cisplatin (P) and daily oral vepesid (VP): A highly active salvage regimen for progressive or recurrent ovarian cancer after platinum therapy by van der Burg, M.E.L., Logmans, A., de Wit, R., van Lent, M., Kruit, W.H.J., Stoter, G., Verweij, J.

Get full text

The role of adoptive immunotherapy in solid cancers by Kruit, W H, Stoter, G

Get more information

Book review by Kruit, W.H.J.

Get full text

Neuropsychiatric side effects of interferon-alfa therapy by Van Gool, Arthur R, Kruit, Wim H J, Engels, Frederike K, Stoter, Gerrit, Bannink, Marjolein, Eggermont, Alexander M M

“…Immunotherapy with interferon-alfa (IFN-alfa) is used in a variety of diseases in- and outside clinical trials (e.g., chronic hepatitis, melanoma, chronic…”
Get more information